Omeed Moaven MD
Hepatobiliary Surgery, Pancreas, Surgical Oncology (Other than Breast)
Associate Professor
Join to View Full Profile
1700 Tulane AveRm 509New Orleans, LA 70112
Phone+1 504-568-4750
Fax+1 504-568-4633
Dr. Moaven is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Omeed Moaven is an HPB/GI surgical oncologist in New Orleans, LA.
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Complex General Surgical Oncology, 2018 - 2020
University of Alabama Medical CenterResidency, Surgery, 2015 - 2018
Massachusetts General HospitalPost-Doctoral Fellowship, 2014 - 2015- Mass General Brigham/Massachusetts General HospitalResidency, Surgery, 2012 - 2014
- Massachusetts General HospitalPost-Doctoral Fellowship, 2011 - 2012
Mashhad University of Medical SciencesClass of 2007
Certifications & Licensure
AL State Medical License 2015 - Present
LA State Medical License 2022 - 2026
FL State Medical License 2020 - 2022
NC State Medical License 2018 - 2022
American Board of Surgery Surgery- American Board of Surgery Complex General Surgical Oncology
Awards, Honors, & Recognition
- Advanced Cancer Therapies 2020 SSO/ACPMP Travel Award Society of Surgical Oncology, 2020
- Deal Fund Travel Award Wake Forest Baptist Comprehensive Cancer Center, 2019
- First place, Cancer paper competition American College of Surgeons North and South Carolina Chapter, 2019
- Join now to see all
Clinical Trials
- Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Start of enrollment: 2020 Oct 13
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Start of enrollment: 2022 Aug 18
Publications & Presentations
PubMed
- Pancreatic tumor microenvironment reprogramming via alloantigenexpressing virotherapy elicits tumor rejection and improves immunotherapy response.Mulu Z Tesfay, Aleksandra Cios, Zetao Cheng, Khandoker U Ferdous, Randal S Shelton
Biorxiv. 2025-09-18 - Disparities in Access to Care in the Multimodal Treatment of Primary Nonmetastatic Liver Cancers and Their Impact on Patient Outcomes.McKenzie Hargis, Denise Danos, Hannah R Malinosky, Aimée Galatas, Syndey McManus
Journal of Surgical Oncology. 2025-07-01 - Decision to operate on hepatocellular cancer patients is not driven by comorbidities in Louisiana.Annie Talbot, Denise Danos, Yong Yi, Lauren Maniscalco, Xiao-Cheng Wu
HPB. 2025-05-01
Authored Content
- Medullary thyroid cancer1/1/2019
- Nature and Clinical Impact of Physiologic Changes Associated With Aging1/1/2018
Press Mentions
University Medical Center Now Offering Hepatic Artery Infusion Pump TherapyApril 1st, 2025- LSU LCMC Health Cancer Center Works to Discover Better Treatments and Improve Pancreatic Cancer Survival Rates in Louisiana and BeyondNovember 3rd, 2024
- Tumor-Killing Viruses Score Rare Success in Late-Stage TrialDecember 7th, 2023
Professional Memberships
- Member
- Member
- Member
- Americas Hepato-Pancreato-Biliary AssociationMember
- Society of Immunotherapy for CancerMember
- Member
Other Languages
- Farsi, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
